Abstract: Disclosed herein, inter alia, are devices, compositions, kits, and methods for interrogating biological samples.

Abstract: Disclosed herein, inter alia, are devices, compositions, kits, and methods for interrogating biological samples.

Abstract: A device comprising: a sample stage configured to be coupled to a microplate receiver; a microplate receiver configured to be coupled to a microplate; at least one heating element thermally coupled to the microplate receiver; a fluidics dispenser configured to dispense one or more reagents into the microplate; and an imaging system configured to detect one or more features in the microplate; and a structure physically coupled to the sample stage, the heating element, the fluidics dispenser, and the imaging system.

Abstract: The present invention relates to a system for performing assays on a solid phase to measure the level of analyte in a sample. Such a system may perform immunoassays using electrochemiluminescence (ECL) including a counterbalanced orbital shaking apparatus for assay consumables.

Abstract: The present invention relates to a system for performing assays on a solid phase to measure the level of analyte in a sample. Such a system may perform immunoassays using electrochemiluminescence (ECL) including a counterbalanced orbital shaking apparatus for assay consumables.

Abstract: A device comprising: a sample stage configured to be coupled to a microplate receiver; a microplate receiver configured to be coupled to a microplate; at least one heating element thermally coupled to the microplate receiver; a fluidics dispenser configured to dispense one or more reagents into the microplate; and an imaging system configured to detect one or more features in the microplate; and a structure physically coupled to the sample stage, the heating element, the fluidics dispenser, and the imaging system.

Abstract: Disclosed herein, inter alia, are devices, compositions, kits, and methods for interrogating biological samples.

Abstract: Disclosed herein, inter alia, are devices, compositions, kits, and methods for interrogating biological samples.

Abstract: The present invention relates to a system for performing assays on a solid phase to measure the level of analyte in a sample. Such a system may perform immunoassays using electrochemiluminescence (ECL) including a counterbalanced orbital shaking apparatus for assay consumables.

Abstract: The present invention relates to a system for performing assays on a solid phase to measure the level of analyte in a sample. Such a system may perform immunoassays using electrochemiluminescence (ECL) including a counterbalanced orbital shaking apparatus for assay consumables.

Abstract: The present invention relates to a system for performing assays on a solid phase to measure the level of analyte in a sample. Such a system may perform immunoassays using electrochemiluminescence (ECL) including a counterbalanced orbital shaking apparatus for assay consumables.

Abstract: The present invention relates to novel muteins of human fibroblast growth factor-21 with reduced susceptibility for proteolytic degradation when expressed in yeast. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.

Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.

Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Abstract: Methods are disclosed for producing recombinant thrombin from precursor molecules that do not require activation by Factor Xa. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of thrombin precursors. Methods for purification of the thrombin precursors are also described. Thrombin precursors produced from transformed or transfected host cells are auto-activated or secreted in an activated form.

Abstract: Novel stretch and blown films are prepared based on copolymers of ethylene and alpha-olefins having (a) a density in the range 0.900 to 0.940 (b) an apparent Mw/Mn of 2-3.4 (c) I21/I2 from 16 to 24 (d) activation energy of flow from 28 to 45 kJ/mol (e) a ratio Ea(HMW)/Ea(LMW) >1.1, and (f) a ratio g?(HMW)/g?(LMW) from 0.85 to 0.95. The films exhibit an excellent combination of strength and processability and are particularly suitable for use as either stretch films or blown films for use as heavy duty sacks. The preferred films show a dart impact of >1100 g and MD elongations of >500%.

Abstract: The present invention provides an expression system for producing a target protein in a host cell comprising a homologously integrated gene encoding T7 RNA polymerase, and a nonintegrated gene encoding a target protein.